Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Pharm Res. 2013 Mar 8;31(6):1469–1476. doi: 10.1007/s11095-013-1008-5

Figure 3.

Figure 3

Bright field image (A), GFP (B) and CY5 (C) fluorescence images of tumor and other major organs from mice bearing orthotopic GFP-expressed PC3 prostate xenograft tumors 2 hours after intravenous injection of CLT1-G2-(Gd-DOTA-MA)-Cy5 at a Cy5 dose of 10 nmol